Classys, which has built a strong brand power in the global medical aesthetics market, is attracting investor attention as it prepares for a full-scale harvest in its largest target market, the United States.
As a leading company in the domestic skin aesthetics equipment industry, we provide an in-depth analysis of Classys' current position and upcoming growth scenarios to drive global diversification.
[Image: /stdaily/uploads/202606/gen_6a38ebf28c77b8.18692708.png]
---
Key Summary
- **Accelerating Global Approvals**: Following the successful launch of its radiofrequency (RF) device 'Volnewmer (US name: Everest)' and microneedle RF 'Quadshai' in the US market, Classys is sequentially proceeding with the US Food and Drug Administration (FDA) clearance process for its high-intensity focused ultrasound (HIFU) device 'Ultraformer MPT (domestic name: Shurink Universe)'.
- **Overseas Revenue Diversification**: The company aims to diversify its portfolio, which has been concentrated in Latin America and Asia, into the global "Big 3" developed markets—the US, Europe, and China—and raise its US revenue share to over 15% in the mid-to-long term.
- **Market Index Analysis**: With the Kosdaq index closing at 968.40, Daily Stock's proprietary Fear & Greed Index showed Kospi at Neutral (52.4, vs. 53.7 a week ago) and Nasdaq at Fear (37.3, vs. 35.5 a week ago), indicating that caution remains dominant in the external environment.
---
Current Status Summary
Classys' current stock price is unconfirmed (latest confirmed closing price as of June 19, 2026: 46,700 KRW), and its recent share price has been undergoing a period of correction from its historical high.
This is analyzed as valuation adjustment pressure resulting from the overhang effect of an 8% block deal by its largest shareholder, Bain Capital, in February, combined with a temporary slowdown in Q1 earnings.
However, the pace of penetration into the US aesthetics market is accelerating.
Based on its partnership with local partner Cartessa Aesthetic, Classys launched 'Everest' at the end of 2024, followed by the official launch of 'Quadshai' in March 2026, diversifying its product lineup in the US.
In addition, the pigment treatment laser device 'Repot' and HIFU device 'Ultraformer MPT' are scheduled to be approved and launched sequentially within this year and next year.
| Key Milestones | US Market Status & Plans | Remarks |
|---|---|---|
| **Everest (Volnewmer)** | Clearance & launch completed at the end of 2024 | Established partnership with Cartessa |
| **Quadshai** | Officially launched in March 2026 | Microneedle RF lineup |
| **Repot** | Scheduled for US launch within 2026 | Laser device for pigment treatment |
| **Ultraformer MPT (Shurink)** | Target FDA clearance by Q1 2027 | Ongoing clinical trials in the US |
---
Financial Analysis
Classys achieved annual revenue of 336.8 billion KRW and an operating profit of 170.6 billion KRW in 2025, recording an astonishing operating margin of 50.7%.
Among many global medical aesthetics companies, it has proven a high fixed-cost leverage effect based on a recurring consumable revenue structure.
However, consolidated financial results for the first quarter of 2026 fell short of market expectations, with revenue of 87.2 billion KRW and operating profit of 37.2 billion KRW.
This is considered a temporary earnings shock caused by accounting adjustments related to the completion of the acquisition of its Brazilian distributor 'Med Systems', concentration of marketing expenses for academic conferences, and temporary costs such as delayed deliveries of new products.
[Image: /stdaily/uploads/202606/gen_6a38ebfd489a60.72096628.png]
---
Valuation
For the full-year 2026 revenue guidance, Classys has proposed a range of 490 billion to 510 billion KRW.
At the current stock price level, the 12-month forward price-to-earnings ratio (Forward PER) is hovering around 20x.
This is at the lower band where valuation attractiveness can be highlighted compared to the historical average multiple of 25x to 30x that the company has enjoyed since its listing.
Once the cumulative installation of devices in the US market passes a critical threshold, highly profitable consumable revenue could grow rapidly.
Experts project that a corporate re-rating scenario will become viable after the second half of 2026, when this trend is expected to materialize in earnest.
---
Expert & Institutional Analysis
Securities analysts are focusing on the long-term direction of Classys' global 'Big 3' market expansion rather than short-term earnings weakness.
In particular, KB Securities evaluated that Classys' long-term growth roadmap is outstanding at a time when the overseas penetration rate of the overall K-aesthetics industry is accelerating.
Kiwoom Securities believes that Q1 2026 is highly likely to be a short-term bottom for earnings, and that the full reflection of profits and losses from the direct operation transition in Brazil and steady equipment exports centered on the US will normalize significantly starting from Q2.
Depending on whether clearances are acquired in major overseas markets, there is also potential for upward revisions to future performance guidelines.
---
Risk Factors
The most immediate risk is the noise surrounding the sale of the remaining stake by the largest shareholder, Bain Capital, and concerns over additional block deals.
Due to the nature of private equity majority shareholders, supply-and-demand uncertainties arising during management sale processes have historically triggered short-term volatility in the stock price.
In addition, high entry barriers for approvals and stringent regulations in advanced global markets are variables that cannot be ignored.
If the FDA approval schedule for 'Ultraformer MPT', a core product in the US, is delayed longer than expected or patent infringement lawsuits from competitors occur, the pace of expanding the US revenue share could slow down.
---
Investment Perspective Summary
Classys is breaking through the limitations of its previous export base, which was centered on South America and Southeast Asia, and is making a name for itself on the global stage, led by the US.
Its business model, where high-margin recurring consumable revenue is generated as the installation base expands after the initial equipment sales stage, is highly attractive.
The current stock price correction is largely a short-term pause that pre-reflects the majority shareholder overhang risk and one-off expenses.
From a long-term perspective, a gradual accumulation strategy while verifying the upward trend of US revenue share could be a reasonable approach.
---
Investor Checklist Q&A
Q1. What is Classys' current revenue share in the US?
A1. Currently, Classys' revenue share in the global Big 3 (US, China, Europe) stands at about 20% of its total overseas revenue, indicating significant potential for future growth.
Q2. What is the synergy with Cartessa Aesthetic, its US partner?
A2. Cartessa is a proven aesthetics distribution specialist in North America, actively supporting the rapid local penetration of Classys' Volnewmer (Everest) and Quadshai into local clinics and hospitals.
Q3. When is the FDA approval for 'Ultraformer MPT' expected?
A3. Investigational Device Exemption (IDE) approval from the FDA was completed in March 2025. Based on ongoing clinical trials in the US, the company aims to obtain final clearance by the first quarter of 2027.
Q4. What was the biggest reason for the Q1 2026 earnings shock?
A4. It was mainly due to initial integration costs and some inventory adjustments following the acquisition of Med Systems, the Brazilian distributor, along with consulting fees for entering China and marketing expenses concentrated in the first half of the year.
Q5. Does the additional overhang risk from Bain Capital persist?
A5. Although supply-and-demand concerns remain following a large-scale block deal (approx. 8% stake) last February, it is expected that they will focus on maximizing the value of the management sale (M&A) while limiting the overhang in the mid-to-long term.
---